Anti-Human Claudin-18.2 (Zolbetuximab) - 100 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CLDN18.2 is a protein that is overexpressed in various cancers, including gastric, pancreatic, and esophageal cancers, making it a valuable therapeutic target. It plays a keyrole in carcinogenesis, cell polarity, and intercellular adhesion. Monoclonal antibodies likezolbetuximab have shown potential in treating advanced cancers with minimal adverseeffects, positioning CLDN18.2 as a promising focus for cancer therapy. A deeperunderstanding of CLDN18.2's functions is crucial for developing effective treatments, especially for patients with poor prognoses1-3. Zolbetuximab (IMAB362) has demonstrated promise in treating advanced gastric andgastroesophageal junction cancers by targeting CLDN18.2. Clinical trials have shown thatZolbetuximab is well-tolerated and effective, inducing antitumor activity through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Preclinical studiesalso support its use in combination with standard chemotherapy, further enhancing itspotential as a cancer treatment4-6.

≥ 5.0 mg/ml

Claudin 18.2 is a highly selective marker with limited expression innormal tissues but is often abnormally expressed in various primary malignant tumors, suchas gastric cancer, pancreatic cancer, and others.